|
ZSCAN20 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.71059999077539E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.06499999988452E-07 |
| Normal-vs-Stage2 |
2.282100E-03 |
| Normal-vs-Stage3 |
8.28899999971711E-07 |
| Normal-vs-Stage4 |
2.40989999955588E-07 |
| Stage1-vs-Stage2 |
4.434200E-01 |
| Stage1-vs-Stage3 |
6.302800E-01 |
| Stage1-vs-Stage4 |
1.169770E-01 |
| Stage2-vs-Stage3 |
3.073000E-01 |
| Stage2-vs-Stage4 |
9.238000E-02 |
| Stage3-vs-Stage4 |
3.388600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.72679997762538E-09 |
| Normal-vs-AfricanAmerican |
6.880500E-03 |
| Normal-vs-Asian |
1.138710E-03 |
| Caucasian-vs-AfricanAmerican |
4.291800E-01 |
| Caucasian-vs-Asian |
3.111600E-01 |
| AfricanAmerican-vs-Asian |
9.838200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.93670000054369E-07 |
| Normal-vs-Female |
2.52849999826665E-08 |
| Male-vs-Female |
8.696800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.60709999996733E-06 |
| Normal-vs-Age(41-60Yrs) |
4.5511000001941E-07 |
| Normal-vs-Age(61-80Yrs) |
2.19850000005017E-06 |
| Normal-vs-Age(81-100Yrs) |
4.10189999999755E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.078000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.654000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.145900E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.117200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.182990E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.062200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.271000E-01 |
| Classical-VS-Follicular |
2.346800E-01 |
| Classical-VS-Other |
7.638200E-02 |
| Classical-VS-Normal |
4.80309999995043E-07 |
| Tall-VS-Follicular |
4.823000E-01 |
| Tall-VS-Other |
2.713600E-01 |
| Tall-VS-Normal |
3.2455999999792E-06 |
| Follicular-VS-Other |
2.475800E-01 |
| Follicular-VS-Normal |
1.70417999999506E-05 |
| Other-VS-Normal |
2.120000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.06290000040966E-07 |
| Normal-vs-N1 |
1.90449999999398E-05 |
| N0-vs-N1 |
3.647600E-01 |
|
|
